Welcome to our dedicated page for Masimo Corporation news (Ticker: $MASI), a resource for investors and traders seeking the latest updates and insights on Masimo Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Masimo Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Masimo Corporation's position in the market.
Masimo (NASDAQ: MASI) will present at the BofA Securities Health Care Conference on May 15, 2024. A live webcast will be available on their website.
Masimo reported strong financial results for the first quarter of 2024 with consolidated revenue at $492.8 million, including healthcare revenue of $339.6 million and non-healthcare revenue of $153.2 million. GAAP net income per diluted share was $0.35 and Non-GAAP net income per diluted share was $0.77. The company saw improvements in gross margins in healthcare and is increasing guidance for healthcare revenues and EPS for 2024. Masimo also announced plans to separate its consumer business.
Masimo, a global leader in monitoring technologies, received FDA clearance for Stork™, an over-the-counter baby monitoring system for infants up to 18 months. The system provides continuous monitoring of oxygen saturation, pulse rate, and skin temperature without a prescription. It offers visual and audible alarms if readings fall outside preset ranges, utilizing advanced pulse oximetry technology. Stork is available at major retailers and online, with additional alarm features through a mobile app update. Stork features a sleek design, patented SET® sensor technology, and a camera with future AI-based features. It is FDA-cleared for OTC use, suitable for infants and neonates in home environments.